{
    "xml": "<topic id=\"PHP5562\" outputclass=\"drug\" rev=\"1.12\" type=\"drug\" namespace=\"/drugs/paclitaxel\" basename=\"paclitaxel\" title=\"PACLITAXEL\">\n<title>PACLITAXEL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_517\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/taxanes/paclitaxel\">Paclitaxel</xref>\n</p>\n<data name=\"vtmid\">67735003</data>\r\n<data name=\"vtmid\">20176411000001103</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_780680770\" title=\"Taxanes\">Taxanes</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP70382\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/paclitaxel\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Paclitaxel is a member of the taxane group of drugs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70346\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/paclitaxel\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of advanced AIDS-related Kaposi's sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only)</p>\n<p outputclass=\"therapeuticIndication\">In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70418\" outputclass=\"cautions\" rev=\"1.27\" parent=\"/drugs/paclitaxel\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">consult product literature</ph>; <ph outputclass=\"caution\">patients aged over 75 years with metastatic adenocarcinoma of the pancreas</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP70336\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/paclitaxel\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (paclitaxel).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70245\" outputclass=\"sideEffects\" rev=\"1.27\" parent=\"/drugs/paclitaxel\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arrhythmia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">febrile neutropenia</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disorders</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">sensory neuropathy</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Bradycardia</ph>; <ph outputclass=\"sideEffect\">cardiac arrest</ph>; <ph outputclass=\"sideEffect\">congestive heart failure</ph>; <ph outputclass=\"sideEffect\">left ventricular dysfunction</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">arrhythmias (nearly always asymptomatic)</ph>; <ph outputclass=\"sideEffect\">asymptomatic hypotension</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">cardiac conduction defects</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">muscle pain</ph>; <ph outputclass=\"sideEffect\">myelosuppression</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">pneumonitis</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Routine premedication with a corticosteroid, an antihistamine and a histamine H<sub>2</sub>-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70410\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/paclitaxel\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70318\" outputclass=\"pregnancy\" parent=\"/drugs/paclitaxel\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (toxicity in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70432\" outputclass=\"breastFeeding\" parent=\"/drugs/paclitaxel\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70363\" outputclass=\"hepaticImpairment\" parent=\"/drugs/paclitaxel\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70186\" outputclass=\"monitoringRequirements\" parent=\"/drugs/paclitaxel\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Cardiac monitoring should be undertaken, particularly if patients have underlying cardiac disease or previous exposure to anthracyclines.</p>\n<p>Patients should be monitored for signs and symptoms of pneumonitis and sepsis.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60025\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.11\" parent=\"/drugs/paclitaxel\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Paclitaxel is available as both conventional and albumin-bound formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.</p>\n<p>Prescribers should specify the brand to be dispensed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70148\" outputclass=\"nationalFunding\" rev=\"1.23\" parent=\"/drugs/paclitaxel\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA55</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Paclitaxel for ovarian cancer (January 2003)</p>\r\n<p>\r\n<i>Either</i> paclitaxel in combination with a platinum compound (cisplatin or carboplatin) <i>or</i> a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA55\">www.nice.org.uk/TA55</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA91</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p>\r\n<p>Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy.</p>\r\n<p>Paclitaxel alone is an options for advanced ovarian cancer in patients who are allergic to platinum compounds.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA91\">www.nice.org.uk/TA91</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA108</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)</p>\r\n<p>Paclitaxel, within its licensed indication, is <b>not</b> recommended for the adjuvant treatment of women with early node-positive breast cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA108\">www.nice.org.uk/TA108</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5562-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/paclitaxel\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75513\" title=\"Solution for infusion\" namespace=\"/drugs/paclitaxel/solution-for-infusion\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75519\" title=\"Powder for suspension for infusion\" namespace=\"/drugs/paclitaxel/powder-for-suspension-for-infusion\">Powder for suspension for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_517\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/taxanes/paclitaxel\" title=\"Paclitaxel\" count=\"1\" rel=\"link\">Paclitaxel</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75513\" namespace=\"/drugs/paclitaxel/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75519\" namespace=\"/drugs/paclitaxel/powder-for-suspension-for-infusion\" title=\"Powder for suspension for infusion\" count=\"1\" rel=\"link\">Powder for suspension for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5562",
    "outputclass": "drug",
    "rev": "1.12",
    "type": "drug",
    "namespace": "/drugs/paclitaxel",
    "basename": "paclitaxel",
    "title": "PACLITAXEL",
    "interactants": [
        {
            "id": "bnf_int_517",
            "label": "Paclitaxel"
        }
    ],
    "vtmid": "20176411000001103",
    "drugClassification": [
        "Taxanes"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Paclitaxel is a member of the taxane group of drugs.",
                "html": "<p>Paclitaxel is a member of the taxane group of drugs.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only)",
                        "html": "Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only)",
                        "html": "Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only)",
                        "html": "Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only)",
                        "html": "Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only)",
                        "html": "Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "Treatment of advanced AIDS-related Kaposi's sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only)",
                        "html": "Treatment of advanced AIDS-related Kaposi's sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only)",
                        "html": "First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only)"
                    },
                    {
                        "textContent": "Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only)",
                        "html": "Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only)"
                    },
                    {
                        "textContent": "In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only)",
                        "html": "In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "consult product literature",
                "html": "consult product literature"
            },
            {
                "type": "cautions",
                "textContent": "patients aged over 75 years with metastatic adenocarcinoma of the pancreas",
                "html": "patients aged over 75 years with metastatic adenocarcinoma of the pancreas"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (paclitaxel).",
                "html": "<p>Appendix 1 (paclitaxel).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Arrhythmia",
                        "html": "Arrhythmia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "febrile neutropenia",
                        "html": "febrile neutropenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal disorders",
                        "html": "gastro-intestinal disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sensory neuropathy",
                        "html": "sensory neuropathy",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Bradycardia",
                        "html": "Bradycardia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "cardiac arrest",
                        "html": "cardiac arrest",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "congestive heart failure",
                        "html": "congestive heart failure",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "left ventricular dysfunction",
                        "html": "left ventricular dysfunction",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arrhythmias (nearly always asymptomatic)",
                        "html": "arrhythmias (nearly always asymptomatic)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "asymptomatic hypotension",
                        "html": "asymptomatic hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cardiac conduction defects",
                        "html": "cardiac conduction defects",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "muscle pain",
                        "html": "muscle pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression",
                        "html": "myelosuppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pneumonitis",
                        "html": "pneumonitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hypersensitivity reactions",
                "textContent": "Routine premedication with a corticosteroid, an antihistamine and a histamine H2-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication.",
                "html": "<p>Routine premedication with a corticosteroid, an antihistamine and a histamine H<sub>2</sub>-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;ensure effective contraception during and for at least 6 months after treatment in men or women.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (toxicity in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (toxicity in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Cardiac monitoring should be undertaken, particularly if patients have underlying cardiac disease or previous exposure to anthracyclines.\n\nPatients should be monitored for signs and symptoms of pneumonitis and sepsis.",
                "html": "<p>Cardiac monitoring should be undertaken, particularly if patients have underlying cardiac disease or previous exposure to anthracyclines.</p><p>Patients should be monitored for signs and symptoms of pneumonitis and sepsis.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Paclitaxel is available as both conventional and albumin-bound formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.\n\nPrescribers should specify the brand to be dispensed.",
                "html": "<p>Paclitaxel is available as both conventional and albumin-bound formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.</p><p>Prescribers should specify the brand to be dispensed.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA55",
                        "label": "www.nice.org.uk/TA55"
                    }
                ],
                "fundingIdentifier": "NICE TA55",
                "textContent": "Paclitaxel for ovarian cancer (January 2003) Either paclitaxel in combination with a platinum compound (cisplatin or carboplatin) or a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).\n\nwww.nice.org.uk/TA55",
                "html": "<p outputclass=\"title\">Paclitaxel for ovarian cancer (January 2003)</p> <p> <i>Either</i> paclitaxel in combination with a platinum compound (cisplatin or carboplatin) <i>or</i> a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA55\">www.nice.org.uk/TA55</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA91",
                        "label": "www.nice.org.uk/TA91"
                    }
                ],
                "fundingIdentifier": "NICE TA91",
                "textContent": "Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005) Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy. Paclitaxel alone is an options for advanced ovarian cancer in patients who are allergic to platinum compounds.\n\nwww.nice.org.uk/TA91",
                "html": "<p outputclass=\"title\">Paclitaxel, pegylated liposomal doxorubicin, and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)</p> <p>Paclitaxel, combined with a platinum compound (carboplatin or cisplatin), is an option for advanced cancer that relapses 6 months or more after completing initial platinum-based chemotherapy. Paclitaxel alone is an option for advanced ovarian cancer that does not respond to, or relapses within 6 months of completing initial platinum-based chemotherapy.</p> <p>Paclitaxel alone is an options for advanced ovarian cancer in patients who are allergic to platinum compounds.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA91\">www.nice.org.uk/TA91</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA108",
                        "label": "www.nice.org.uk/TA108"
                    }
                ],
                "fundingIdentifier": "NICE TA108",
                "textContent": "Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) Paclitaxel, within its licensed indication, is not recommended for the adjuvant treatment of women with early node-positive breast cancer.\n\nwww.nice.org.uk/TA108",
                "html": "<p outputclass=\"title\">Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)</p> <p>Paclitaxel, within its licensed indication, is <b>not</b> recommended for the adjuvant treatment of women with early node-positive breast cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA108\">www.nice.org.uk/TA108</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75513",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75519",
                "label": "Powder for suspension for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_517",
                "label": "Paclitaxel",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75513",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75519",
                "label": "Powder for suspension for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}